Literature DB >> 16629416

Human demyelinating disease and the polyomavirus JCV.

K Khalili1, M K White.   

Abstract

Many human neurological diseases involve demyelination of the central and/or peripheral nervous systems. These include the hereditary leukodystrophies--which have a genetic basis; multiple sclerosis (MS)--where the underlying cause of demyelination remains unknown; and progressive multifocal leukoencephalopathy (PML)--where the etiology is well-established as being viral. The human neurotropic polyomavirus--JC virus (JCV)--is the etiologic agent of PML, a fatal demyelinating disease of the central nervous system that occurs mainly in immunosuppressed patients, especially those with HIV/AIDS. JCV belongs to the polyomavirus family of tumor viruses that are characterized by non-enveloped icosahedral capsids containing small, circular, double-stranded DNA genomes. Serological studies have shown that JCV is widespread throughout the human population, but infections are usually restricted by the immune system, particularly cell-mediated immunity, causing the virus to enter a latent phase. An important corollary of this is that situations of severe immunosuppression may permit JCV to replicate and are thus a risk factor for PML.

Entities:  

Mesh:

Year:  2006        PMID: 16629416     DOI: 10.1191/135248506ms1264oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

1.  Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Authors:  Juliene K G Co; Saguna Verma; Ulziijargal Gurjav; Laarni Sumibcay; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2007-07-20       Impact factor: 5.226

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA.

Authors:  E Iacobaeus; C Ryschkewitsch; M Gravell; M Khademi; E Wallstrom; T Olsson; L Brundin; Eo Major
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

4.  JC virus-induced Progressive Multifocal Leukoencephalopathy.

Authors:  A Sami Saribas; Ahmet Ozdemir; Cathy Lam; Mahmut Safak
Journal:  Future Virol       Date:  2010-05       Impact factor: 1.831

5.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Authors:  Peter Rieckmann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

6.  JC virus agnoprotein inhibits in vitro differentiation of oligodendrocytes and promotes apoptosis.

Authors:  Nana Merabova; Dorota Kaniowska; Rafal Kaminski; Satish L Deshmane; Martyn K White; Shohreh Amini; Armine Darbinyan; Kamel Khalili
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

7.  Neuroinflammation resulting from covert brain invasion by common viruses - a potential role in local and global neurodegeneration.

Authors:  Jeannine A Majde
Journal:  Med Hypotheses       Date:  2010-03-16       Impact factor: 1.538

Review 8.  [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].

Authors:  H-P Hartung; C Warnke; R Hohlfeld; B C Kieseier
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

Review 9.  JC virus: an oncogenic virus in animals and humans?

Authors:  Melissa S Maginnis; Walter J Atwood
Journal:  Semin Cancer Biol       Date:  2009-02-24       Impact factor: 15.707

10.  Hypoxia inducible factor-1 alpha activation of the JCV promoter: role in the pathogenesis of progressive multifocal leukoencephalopathy.

Authors:  Sergio Piña-Oviedo; Kamel Khalili; Luis Del Valle
Journal:  Acta Neuropathol       Date:  2009-04-10       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.